Black Rock Inc. Gracell Biotechnologies Inc. Transaction History

Black Rock Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$2.43 - $10.04 $47,316 - $195,498	-19,472 Reduced 3.48%	539,973 $5.42 Million
Q3 2023 Nov 13, 2023	BUY	$2.83 - $4.9 $118,961 - $205,976	42,036 Added 8.12%	559,445 $1.61 Million
Q2 2023 Aug 11, 2023	SELL	$1.45 - $6.07 $56,152 - $235,066	-38,726 Reduced 6.96%	517,409 $1.97 Million
Q1 2023 May 12, 2023	SELL	$1.8 - $2.5 $758,572 - $1.05 Million	-421,429 Reduced 43.11%	556,135 $1.03 Million
Q4 2022 Feb 13, 2023	BUY	$2.08 - $3.96 $47,228 - $89,915	22,706 Added 2.38%	977,564 $2.25 Million
Q3 2022 Nov 14, 2022	SELL	$2.08 - $5.15 $112,923 - $279,593	-54,290 Reduced 5.38%	954,858 $3.08 Million
Q2 2022 Aug 12, 2022	BUY	$1.95 - $5.5 $164,808 - $464,843	84,517 Added 9.14%	1,009,148 $5.55 Million
Q1 2022 May 12, 2022	BUY	$1.83 - $5.52 $265,240 - $800,068	144,940 Added 18.59%	924,631 $2.15 Million
Q4 2021 Feb 10, 2022	SELL	$5.65 - $14.9 $868,789 - $2.29 Million	-153,768 Reduced 16.47%	779,691 $4.71 Million
Q3 2021 Nov 09, 2021	SELL	$9.91 - $14.84 $268,323 - $401,807	-27,076 Reduced 2.82%	933,459 $12.9 Million
Q2 2021 Aug 11, 2021	BUY	$9.75 - $18.42 $9.37 Million - $17.7 Million	960,535 New	960,535 $12.5 Million

75.1K

Ticker GRCL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,674,096
Description
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the tre...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.